Related Experiment Video
Updated: Jun 11, 2026
Initial Evaluation of Antibody-conjugates Modified with Viral-derived Peptides for Increasing Cellular Accumulation and Improving Tumor Targeting
Published on: March 8, 2018
Protease-activatable organometal-Peptide bioconjugates with enhanced cytotoxicity on cancer cells
Katrin Splith1, Wanning Hu, Ulrich Schatzschneider
1Institut fur Biochemie, Fakultat fur Biowissenschaften, Pharmazie und Psychologie, D-04103 Leipzig, Germany.
Abstract:
Over the past years, numerous promising new metalorganic lead structures have been developed exhibiting highly active cytostatic properties. However, the efficiency of such chemotherapeutics in the treatment of tumors is often limited by their low therapeutic index due to their short half-life, lack of tumor selectivity, and associated side effects. Furthermore, the membrane barrier often restricts their cellular uptake by passive diffusion. In this contribution, we describe the synthesis, cellular uptake, and biologic activity of a series of cymantrene-peptide conjugates. Cymantrene CpMn(CO)(3) is a robust organometallic group, which is stable in air and water and easy to functionalize. In this work, some new cymantrene derivatives with different linkers between the half-sandwich complex and the carboxylate group were attached to the cell-penetrating peptide sC18 that should act as a transporter for the metal moiety. All conjugates were characterized for their cytotoxic activity on human breast adenocarcinoma cells (MCF-7) and human colon carcinoma cells (HT-29). We found that bioconjugates bearing two cymantrene groups were more active than the monofunctionalized ones. By the introduction of a cathepsin B cleavage site next to the organometallic group, the biologic activity could be in increased even further. Fluorescence microscopy studies and apoptosis assays gave preliminary hints on the mode of action of these systems.
Insights
New cymantrene-peptide conjugates show enhanced anticancer activity. Attaching two cymantrene groups and a cathepsin B cleavage site to cell-penetrating peptides improved efficacy against breast and colon cancer cells.
Area of Science:
- Organometallic Chemistry
- Medicinal Chemistry
- Cell Biology
Background:
- Metal-organic compounds show promise as cytostatic agents but face limitations like short half-life and poor tumor selectivity.
- Cellular uptake of chemotherapeutics is often hindered by membrane barriers, limiting passive diffusion.
- Cymantrene (CpMn(CO)3) is a stable, functionalizable organometallic moiety suitable for developing new therapeutic agents.
Purpose of the Study:
- To synthesize and evaluate novel cymantrene-peptide conjugates for enhanced anticancer properties.
- To investigate the role of cymantrene loading and specific cleavage sites in cellular uptake and biologic activity.
- To explore the mechanism of action of these novel conjugates in cancer cells.
Main Methods:
- Synthesis of cymantrene derivatives functionalized with varying linkers.
- Attachment of cymantrene derivatives to the cell-penetrating peptide sC18.
- Cytotoxic activity assays on human breast adenocarcinoma (MCF-7) and colon carcinoma (HT-29) cells.
- Fluorescence microscopy and apoptosis assays to study cellular uptake and mode of action.
Main Results:
- Bioconjugates with two cymantrene groups exhibited higher cytotoxic activity than monofunctionalized conjugates.
- Incorporation of a cathepsin B cleavage site further enhanced the biologic activity of the cymantrene-peptide conjugates.
- Preliminary studies suggested specific mechanisms of action involving cellular uptake and apoptosis induction.
Conclusions:
- Cymantrene-peptide conjugates represent a promising strategy to overcome limitations of traditional metal-organic chemotherapeutics.
- Optimizing cymantrene loading and incorporating enzyme-cleavable linkers can significantly improve anticancer efficacy.
- Further investigation into the mode of action is warranted to fully elucidate their therapeutic potential.
